Rosacea 2026: phenotypes, triggers, and treatment

Rosacea is a common, chronic inflammatory condition of the central face. Contemporary care has moved away from sorting patients into fixed subtypes and toward a phenotype approach: treatment is matched to the specific features a person has, such as transient flushing, persistent redness, inflammatory papules and pustules, visible blood vessels, thickened skin, and eye involvement [1][3]. This shift matters in practice, because the agents that calm background redness differ from those that clear inflammatory bumps, and combination therapy is recommended when several features coexist [1].

This article outlines how rosacea is recognized and treated feature by feature, drawing on the global ROSacea COnsensus recommendations and a GRADE-assessed systematic review of rosacea interventions. It is not medical advice; diagnosis and treatment should be directed by a board-certified dermatologist.

From subtypes to phenotypes

Earlier frameworks divided rosacea into subtypes, which did not capture the way features overlap in real patients. The ROSCO panels and aligned working groups now recommend assessing each presenting feature and treating accordingly, with complete clearance set as the primary goal because clearing fully is associated with longer periods of remission than partial improvement [1]. Consensus guidance also recommends discussing the burden of the condition with patients, since rosacea affects quality of life beyond what its visible severity suggests [1].

Recognizing the features

• Transient flushing: episodic warmth and redness triggered by heat, alcohol, spicy food, stress, or temperature change.
• Persistent erythema: fixed background redness across the cheeks, nose, chin, or forehead.
• Papules and pustules: inflammatory bumps that can resemble acne but without the comedones (blackheads and whiteheads) typical of acne.
• Telangiectasia: small, visible, fixed blood vessels.
• Phymatous change: skin thickening, most often of the nose, that develops over time in some patients.
• Ocular features: dryness, grittiness, burning, and inflamed lid margins, which can occur with or without skin signs [1].

Trigger control and skin care

Identifying individual triggers and reducing them is a foundation of management. Frequently reported triggers include sun exposure, heat, hot beverages, spicy food, alcohol, and emotional stress, though they differ between people. Daily broad-spectrum sun protection and gentle, non-irritating skin care support every other treatment and are recommended as baseline measures [1][3]. Our summer photoprotection guide covers sun protection in more detail.

Treating by feature

The GRADE-assessed systematic review graded the certainty of evidence for each option, which helps prioritize choices [2]:

Persistent redness

Topical brimonidine has high-certainty evidence and topical oxymetazoline has moderate-certainty evidence for temporarily reducing persistent redness [2]. These agents constrict superficial vessels and act for hours rather than permanently, so they are used as needed alongside other treatments.

Papules and pustules

Topical azelaic acid and topical ivermectin both have high-certainty evidence for reducing inflammatory lesions, and modified-release doxycycline 40 mg has moderate-to-high-certainty evidence; topical metronidazole and minocycline are also effective, and isotretinoin is an option for resistant cases [2]. Newer topical options reviewed in recent consensus include microencapsulated benzoyl peroxide and minocycline foam, the latter offering inflammatory-lesion benefit with less systemic exposure than oral minocycline [4].

Visible vessels

For fixed telangiectasia and the redness driven mainly by visible vessels, laser and intense pulsed light therapy have low-to-moderate-certainty evidence and are the usual approach, since topical agents do not remove established vessels [2].

Thickened skin (phyma)

Established phymatous change is treated procedurally, for example with ablative lasers or surgical recontouring, typically once the inflammatory component is controlled.

Eye involvement

Ocular rosacea is managed with lid hygiene and artificial tears, with oral omega-3 fatty acids showing moderate-certainty benefit in the review; anything beyond mild involvement warrants ophthalmology referral [1][2].

Adverse events, limitations, and realistic expectations

• Chronic, relapsing course. Rosacea is managed over time, and maintenance treatment is often needed to hold results [1].
• Topical vasoconstrictors are temporary and can occasionally be followed by rebound redness; they reduce background redness for hours rather than treating vessels [2].
• Common side effects of topical anti-inflammatory agents include stinging, dryness, and irritation, particularly on sensitive rosacea-prone skin.
• Oral therapy considerations. Sub-antimicrobial-dose doxycycline limits antibiotic exposure; isotretinoin requires pregnancy prevention and monitoring.
• Vascular laser usually requires more than one session, and results vary; bruising and temporary pigment change can occur.
• Evidence gaps remain for several features, and certainty is lower for telangiectasia and phyma than for inflammatory lesions [2][4].

Bottom line

Rosacea is best treated by its features rather than as a single disease. Persistent redness responds to topical vasoconstrictors or vascular laser, inflammatory papules and pustules to azelaic acid, ivermectin, or modified-release doxycycline, and ocular involvement to lid care and referral, with trigger control and sun protection underpinning all of it [1][2][4]. Because rosacea is chronic, the realistic goal is sustained clearance through targeted treatment and maintenance rather than a one-time fix.

This article is for informational purposes and does not constitute medical advice.